In this episode of The OncoloGIST, myeloma experts discuss the abstracts they most anticipated at IMS 2026, including EXCALIBER-RRMM and PERSEUS.
Gurbakhash Kaur, MD
Advertisement
Gurbakhash Kaur, MD, is an assistant professor of internal medicine at Mount Sinai Health System.
Articles by Gurbakhash Kaur, MD
Gurbakhash Kaur, MD, discusses how quadruplet regimens, CAR T-cell therapy, and bispecific antibodies are reshaping the role of autologous transplant in multiple myeloma.
Advertisement
Latest Updated Articles
Myeloma Experts Discuss Key Abstracts From the 2026 IMS MeetingOctober 14th 2026
Kaur Discusses the Declining Role of Autologous Transplant in MyelomaSeptember 24th 2026
Advertisement
Advertisement
Trending on Targeted Onc
1
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
2
Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma
3
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
4
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
5